Jonathan Santoro
Neurology with Special Qualifications in Child Neurology · Palo Alto, CANPI 1053754614
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $28,733 of the $41,139 with a category attached, or 69.8%. 12 manufacturers reported payments, led by UCB SA at 50.3% of the total. 2025 is the largest year on record at $13,000, 9.9 times the $1,313 reported in 2019. Among neurology with special qualifications in child neurology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 51 payments — averaging $806.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$21K
- Cycle Pharmaceuticals Inc$9K
- Amgen$5K
- Immedica Pharma US, Inc.$2K
- Biogen$1K
- AstraZeneca$1K
- plus $3K from 6 others
Across 25 payments — averaging $57,435 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.4M
- Boehringer Ingelheim International GmbH$23K
- Biogen$21K
- UCB, Inc.$6K
What the payments were for
- Consulting fees$28,73370%
- Speaking & faculty fees$9,55923%
- Grants$1,0002%
- Food & beverage$1,8374%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 7 | $20,705 |
| Cycle Pharmaceuticals Inc | 5 | $8,696 |
| Amgen(2 entities) | 2 | $4,558 |
| Immedica Pharma US, Inc. | 4 | $1,950 |
| Biogen | 14 | $1,226 |
| AstraZeneca | 3 | $1,102 |
| Sanofi | 1 | $1,000 |
| Alnylam Pharmaceuticals Inc. | 1 | $533 |
| ZOLL Medical Corporation | 1 | $517 |
| TG Therapeutics, Inc. | 4 | $472 |
| UCB, Inc. | 4 | $201 |
| Novartis | 5 | $179 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,139 in reported general payments places this provider in the 90th percentile of 216 neurology with special qualifications in child neurology providers in California.
See all neurology with special qualifications in child neurology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 74 | $478,825 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 20 | $220,088 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 11 | $63,301 |
| Lorazepam | 38 | $374 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Palo Alto
- Jennifer O'MalleyPalo Alto$46K
- Cynthia CampenPalo Alto$9K
- Sonia PartapPalo Alto$6K
- Jenna KlotzPalo Alto$5K
- Michael ChezSacramento$374K
- Allen BottOakland$372K
- Joseph SullivanSan Francisco$240K
- Ann SegerenStanford$172K
- Rajsekar RajaramanLos Angeles$134K
- Deborah HolderLos Angeles$130K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.